Thomas Smith
Stock Analyst at Leerink Partners
(2.24)
# 2,630
Out of 5,182 analysts
58
Total ratings
35.85%
Success rate
10.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGMB AgomAb Therapeutics NV | Initiates: Outperform | $36 | $9.85 | +265.48% | 1 | Mar 3, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $5.30 | +126.42% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $22.71 | +40.91% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $27.13 | +54.81% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.80 | -44.44% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $5.47 | +64.53% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $3.95 | +77.22% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $6.15 | +534.15% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $5.59 | +365.12% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $118.96 | -83.19% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $785.07 | -44.59% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $66.27 | -45.68% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.63 | +166.16% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $24.73 | -15.08% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $14.47 | +210.99% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $13.07 | -54.09% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.61 | +129.89% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.19 | +320.17% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $18.60 | -8.60% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $32.41 | +97.47% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $15.71 | +345.58% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.13 | +730.67% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $33.67 | -64.36% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $12.55 | +537.45% | 2 | Dec 8, 2020 |
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Outperform
Price Target: $36
Current: $9.85
Upside: +265.48%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $5.30
Upside: +126.42%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $22.71
Upside: +40.91%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $27.13
Upside: +54.81%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.80
Upside: -44.44%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $5.47
Upside: +64.53%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $3.95
Upside: +77.22%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $6.15
Upside: +534.15%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $5.59
Upside: +365.12%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $118.96
Upside: -83.19%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $785.07
Upside: -44.59%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $66.27
Upside: -45.68%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.63
Upside: +166.16%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $24.73
Upside: -15.08%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $14.47
Upside: +210.99%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $13.07
Upside: -54.09%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $2.61
Upside: +129.89%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.19
Upside: +320.17%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $18.60
Upside: -8.60%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $32.41
Upside: +97.47%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $15.71
Upside: +345.58%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.13
Upside: +730.67%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $33.67
Upside: -64.36%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $12.55
Upside: +537.45%